SRS Study in Patients With Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

141 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-21

Study Completion Date

2017-06-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical research study is to learn if stereotactic body radiotherapy (SBRT) can help to control NSCLC. The safety of SBRT will also be studied.

Objectives:

To assess therapeutic efficacy and toxicities of stereotactic body radiotherapy (SBRT) for patients with medically inoperable stage I (T1-2, N0,M0), selective stage II (chest wall T3, N0M0) or isolated peripheral lung recurrent non-small cell lung cancer (NSCLC).

Primary goal: Improve 2 years progression free survival at the treated primary tumor site.

Secondary goals:

1. Improve disease free survival, disease specific survival and overall survival at 2 years.
2. Decrease grade 3 and above acute and/or chronic toxicities.
3. Collect blood for future biomarkers study

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

NCT00087438

Lung Cancer

COMPLETED PHASE2

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00551369

Lung Cancer

COMPLETED PHASE2

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00750269

Lung Cancer

COMPLETED PHASE1/PHASE2

A Phase I/II Trial of Stereotactic Body Radiation Therapy

NCT00591838

Inoperable Stage I/II Non-small Cell Lung Cancer

COMPLETED PHASE1/PHASE2

Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors

NCT00632281

Lung Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Stereotactic body radiotherapy is designed to provide an image guided, more focused, dose escalated radiotherapy over a shorter time frame (1 week rather than 7 weeks) than conventional radiation therapy. The goal of SBRT is to improve tumor control while reducing the side effects.

If you are found to be eligible to take part in this study, you will receive daily SBRT for 4 days in a row over a 45 minute time period. During the treatment, you will lie still on a table for about 45 minutes per day in the same position. The machine will deliver the dose according to the plan developed by the doctor and the dose will be controlled by a computer.

During the treatment, you will be seen by a doctor and research nurse once a week to evaluate possible side effects. A physical exam and a medical history will be done at these visits.

You will be taken off study early if the disease gets worse or intolerable side effects occur.

You will have a follow-up visit 6 weeks after completion of radiotherapy to check for side effects. You will continue to have follow-up visits that will decrease in frequency over time. You will have imaging tests (chest CT or positron emission computed tomography (PET) scan) and routine blood tests (about 2 teaspoons) at these follow-up visits.

This is an investigational study. SBRT is FDA approved for the treatment of lung cancer. About 138 patients will take part in this study. All will be enrolled at MD Anderson.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Stereotactic Body Radiation Therapy (SBRT) Stage I NSCLC

Group Type EXPERIMENTAL

Stereotactic Body Radiation Therapy (SBRT)

Intervention Type PROCEDURE

Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments

Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments

Cohort 2

Stereotactic Body Radiation Therapy (SBRT) Selective Stage II NSCLC

Group Type EXPERIMENTAL

Stereotactic Body Radiation Therapy (SBRT)

Intervention Type PROCEDURE

Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments

Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments

Cohort 3

Stereotactic Body Radiation Therapy (SBRT) Isolated Peripheral Lung Recurrent NSCLC

Group Type EXPERIMENTAL

Stereotactic Body Radiation Therapy (SBRT)

Intervention Type PROCEDURE

Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments

Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stereotactic Body Radiation Therapy (SBRT)

Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments

Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Cohort 1: Histologically or cytologically documented NSCLC.
2. Cohort 1: Inoperable stage IA (T1N0MO), IB (T2N0MO) and selective stage II (T3 due to chest wall involvement, N0M0). Patient refuses surgery is eligible. Secondary lung cancer is eligible if primary cancers have been cured or stable with life expectance longer than 2 years. If primary cancer is lung cancer, patient needs to be lung cancer free for more than 5 year for same histology or more than 2 years for different histology.
3. Cohort 1: Patients with hilar or mediastinal lymph nodes \<= 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with \> 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but on-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. Patient who received induction chemotherapy or other systemic therapy are eligible.
4. Cohort 1: Performance score Karnofsky performance status (KPS) 60-100.
5. Cohort 2: Histologically or cytologically documented NSCLC.
6. Cohort 2: Inoperable isolated lung parenchyma recurrent NSCLC without evidence of lymph node or mediastinal involvement (clinical stage T1-2, chest wall involvement T3, N0M0) after surgical resection or definitive radiotherapy with/without chemotherapy. Recurrent disease is defined as NSCLC with same histology, same lobe that recurs within 5 years after initial definitive therapy. Patient refuses surgery is also eligible. Patient received systemic therapy is eligible.
7. Cohort 2: Performance score KPS 60-100.
8. Cohort 3: Histologically or cytologically documented NSCLC.
9. Cohort 3: Previous history of NSCLC that has been cured or stable. New development of inoperable isolated lung parenchyma lesion that has been documented histologically or cytologically as NSCLC without evidence of lymph node or mediastinal involvement (clinical stage T1-2, chest wall involvement T3, N0M0) and not eligible for cohort 1 and recurrent disease as defined in Cohort 2. This includes NSCLC happens within 5 years after initial definitive treatment of prior NSCLC, and/or is located in the different lobes.
10. (cont.) Cohort 3: Possible stage IV disease is eligible as long as it meets the criteria above since there is no definitive way to confirm it. Patient refuses surgery is eligible. Patient received systemic therapy is eligible.
11. Cohort 3: Performance score KPS 60-100.

Exclusion Criteria

1. Any tumor involving main bronchus, major vessels, heart, esophagus, trachea, carina, spinal cord.
2. Any tumor that causes collapsed lobe of lung.
3. Any tumor with malignant pleural effusion.
4. Direct evidence of hilar, mediastinal lymph node or distant metastasis based on staging work up.
5. Pregnancy. Patients (men and women) of child bearing potential should use an effective (for them) method of birth control throughout their participation in this study.

Eligible Sex

ALL

Accepts Healthy Volunteers

No